GLPwatch
Defining the role of GLP-1 receptor agonists for individualized treatment of Type 2 diabetes.
Expert Rev Endocrinol Metab · 2014
Last updated 2026-05-28GLP-1 receptor agonists (GLP-1 RAs) are a type of diabetes medication that help control blood sugar levels in people with Type 2 diabetes. They work differently depending on whether they act quickly or slowly in the body, which affects how they are used in treatment. These drugs also impact organs beyond the pancreas, but more research is needed to fully understand the best ways to use them.
AI summary of the abstract below.
| Journal | Expert Rev Endocrinol Metab, 2014 |
|---|---|
| Citations | 13 |
| Relative citation ratio | 0.46 |
| NIH percentile | 27 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes |
Abstract
With the advent of dipeptidyl peptidase (DPP)-4 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) over the past decade, incretin therapy has become established as an important treatment strategy for Type 2 diabetes mellitus (T2DM), with an efficacy and safety profile distinct from that of other anti-hyperglycemic agents. However, our understanding of the optimal clinical use of incretins remains incomplete. This review focuses on the use of GLP-1 RAs in the treatment of T2DM, with reference to the differing dominant mechanisms of action between short- and long-acting GLP-1 RAs and the clinical implications of this difference. The role of GLP-1 and the effects of GLP-1 RAs in various organs other than the pancreas will also be discussed.
Verbatim abstract via PubMed 30736202 ↗